BACKGROUND: Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC). METHODS: To identify genetic variants associated with poor overall survival in these patients, we conducted a genome-wide scan of 307,260 single-nucleotide polymorphisms (SNPs) in 327 advanced-stage NSCLC patients who received platinum-based chemotherapy with or without radiation at the University of Texas MD Anderson Cancer Center (the discovery population). A fast-track replication was performed for 315 patients from the Mayo Clinic followed by a second validation at the University of Pittsburgh in 420 patients enrolled in the Spanish Lung Cancer Group PLATAX clinical trial. A pooled analysis combining the Mayo Clinic and PLATAX populations or all three populations was also used to validate the results. We assessed the association of each SNP with overall survival by multivariable Cox proportional hazard regression analysis. All statistical tests were two-sided. RESULTS: SNP rs1878022 in the chemokine-like receptor 1 (CMKLR1) was statistically significantly associated with poor overall survival in the MD Anderson discovery population (hazard ratio [HR] of death = 1.59, 95% confidence interval [CI] = 1.32 to 1.92, P = 1.42 × 10(-6)), in the PLATAX clinical trial (HR of death = 1.23, 95% CI = 1.00 to 1.51, P = .05), in the pooled Mayo Clinic and PLATAX validation (HR of death = 1.22, 95% CI = 1.06 to 1.40, P = .005), and in pooled analysis of all three populations (HR of death = 1.33, 95% CI = 1.19 to 1.48, P = 5.13 × 10(-7)). Carrying a variant genotype of rs10937823 was associated with decreased overall survival (HR of death = 1.82, 95% CI = 1.42 to 2.33, P = 1.73 × 10(-6)) in the pooled MD Anderson and Mayo Clinic populations but not in the PLATAX trial patient population (HR of death = 0.96, 95% CI = 0.69 to 1.35). CONCLUSION: These results have the potential to contribute to the future development of personalized chemotherapy treatments for individual NSCLC patients.
BACKGROUND: Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC). METHODS: To identify genetic variants associated with poor overall survival in these patients, we conducted a genome-wide scan of 307,260 single-nucleotide polymorphisms (SNPs) in 327 advanced-stage NSCLCpatients who received platinum-based chemotherapy with or without radiation at the University of Texas MD Anderson Cancer Center (the discovery population). A fast-track replication was performed for 315 patients from the Mayo Clinic followed by a second validation at the University of Pittsburgh in 420 patients enrolled in the Spanish Lung Cancer Group PLATAX clinical trial. A pooled analysis combining the Mayo Clinic and PLATAX populations or all three populations was also used to validate the results. We assessed the association of each SNP with overall survival by multivariable Cox proportional hazard regression analysis. All statistical tests were two-sided. RESULTS: SNP rs1878022 in the chemokine-like receptor 1 (CMKLR1) was statistically significantly associated with poor overall survival in the MD Anderson discovery population (hazard ratio [HR] of death = 1.59, 95% confidence interval [CI] = 1.32 to 1.92, P = 1.42 × 10(-6)), in the PLATAX clinical trial (HR of death = 1.23, 95% CI = 1.00 to 1.51, P = .05), in the pooled Mayo Clinic and PLATAX validation (HR of death = 1.22, 95% CI = 1.06 to 1.40, P = .005), and in pooled analysis of all three populations (HR of death = 1.33, 95% CI = 1.19 to 1.48, P = 5.13 × 10(-7)). Carrying a variant genotype of rs10937823 was associated with decreased overall survival (HR of death = 1.82, 95% CI = 1.42 to 2.33, P = 1.73 × 10(-6)) in the pooled MD Anderson and Mayo Clinic populations but not in the PLATAX trial patient population (HR of death = 0.96, 95% CI = 0.69 to 1.35). CONCLUSION: These results have the potential to contribute to the future development of personalized chemotherapy treatments for individual NSCLCpatients.
Authors: S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg Journal: N Engl J Med Date: 2008-01-16 Impact factor: 91.245
Authors: Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston Journal: Nat Genet Date: 2008-04-02 Impact factor: 38.330
Authors: Xifeng Wu; Charles Lu; Yuanqing Ye; Joe Chang; Hushan Yang; Jie Lin; Jian Gu; Waun Ki Hong; David Stewart; Margaret R Spitz Journal: Pharmacogenet Genomics Date: 2008-11 Impact factor: 2.089
Authors: Rayjean J Hung; James D McKay; Valerie Gaborieau; Paolo Boffetta; Mia Hashibe; David Zaridze; Anush Mukeria; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Chu Chen; Gary Goodman; John K Field; Triantafillos Liloglou; George Xinarianos; Adrian Cassidy; John McLaughlin; Geoffrey Liu; Steven Narod; Hans E Krokan; Frank Skorpen; Maiken Bratt Elvestad; Kristian Hveem; Lars Vatten; Jakob Linseisen; Françoise Clavel-Chapelon; Paolo Vineis; H Bas Bueno-de-Mesquita; Eiliv Lund; Carmen Martinez; Sheila Bingham; Torgny Rasmuson; Pierre Hainaut; Elio Riboli; Wolfgang Ahrens; Simone Benhamou; Pagona Lagiou; Dimitrios Trichopoulos; Ivana Holcátová; Franco Merletti; Kristina Kjaerheim; Antonio Agudo; Gary Macfarlane; Renato Talamini; Lorenzo Simonato; Ray Lowry; David I Conway; Ariana Znaor; Claire Healy; Diana Zelenika; Anne Boland; Marc Delepine; Mario Foglio; Doris Lechner; Fumihiko Matsuda; Helene Blanche; Ivo Gut; Simon Heath; Mark Lathrop; Paul Brennan Journal: Nature Date: 2008-04-03 Impact factor: 49.962
Authors: Thorgeir E Thorgeirsson; Frank Geller; Patrick Sulem; Thorunn Rafnar; Anna Wiste; Kristinn P Magnusson; Andrei Manolescu; Gudmar Thorleifsson; Hreinn Stefansson; Andres Ingason; Simon N Stacey; Jon T Bergthorsson; Steinunn Thorlacius; Julius Gudmundsson; Thorlakur Jonsson; Margret Jakobsdottir; Jona Saemundsdottir; Olof Olafsdottir; Larus J Gudmundsson; Gyda Bjornsdottir; Kristleifur Kristjansson; Halla Skuladottir; Helgi J Isaksson; Tomas Gudbjartsson; Gregory T Jones; Thomas Mueller; Anders Gottsäter; Andrea Flex; Katja K H Aben; Femmie de Vegt; Peter F A Mulders; Dolores Isla; Maria J Vidal; Laura Asin; Berta Saez; Laura Murillo; Thorsteinn Blondal; Halldor Kolbeinsson; Jon G Stefansson; Ingunn Hansdottir; Valgerdur Runarsdottir; Roberto Pola; Bengt Lindblad; Andre M van Rij; Benjamin Dieplinger; Meinhard Haltmayer; Jose I Mayordomo; Lambertus A Kiemeney; Stefan E Matthiasson; Hogni Oskarsson; Thorarinn Tyrfingsson; Daniel F Gudbjartsson; Jeffrey R Gulcher; Steinn Jonsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nature Date: 2008-04-03 Impact factor: 49.962
Authors: Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson Journal: Nature Date: 2008-10-23 Impact factor: 49.962
Authors: Linda Kachuri; Jens Helby; Stig Egil Bojesen; David C Christiani; Li Su; Xifeng Wu; Adonina Tardón; Guillermo Fernández-Tardón; John K Field; Michael P Davies; Chu Chen; Gary E Goodman; Frances A Shepherd; Natasha B Leighl; Ming S Tsao; Yonathan Brhane; M Catherine Brown; Kevin Boyd; Daniel Shepshelovich; Lei Sun; Christopher I Amos; Geoffrey Liu; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-07 Impact factor: 4.254
Authors: Carissa C Jones; William S Bush; Dana C Crawford; Angela S Wenzlaff; Ann G Schwartz; John K Wiencke; Margaret R Wrensch; William J Blot; Stephen J Chanock; Eric L Grogan; Melinda C Aldrich Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-15 Impact factor: 4.254
Authors: Joel L Weissfeld; Brenda Diergaarde; Tomoko Nukui; Shama Buch; Arjun Pennathur; Mark A Socinski; Jill M Siegfried; Marjorie Romkes Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Xifeng Wu; Liang Wang; Yuanqing Ye; Jeremiah A Aakre; Xia Pu; Gee-Chen Chang; Pan-Chyr Yang; Jack A Roth; Randolph S Marks; Scott M Lippman; Joe Y Chang; Charles Lu; Claude Deschamps; Wu-Chou Su; Wen-Chang Wang; Ming-Shyan Huang; David W Chang; Yan Li; V Shane Pankratz; John D Minna; Waun Ki Hong; Michelle A T Hildebrandt; Chao Agnes Hsiung; Ping Yang Journal: Cancer Res Date: 2013-05-23 Impact factor: 12.701